In a game with a name like Party Animals, it certainly wouldn’t be much of a party without plenty of adorable characters to choose from. As one of the standout features, there’s not only a vibrant ...

Character.AI has stopped users under 18 from accessing its chatbots and launched a new feature called Stories as a replacement, following rising concerns about the mental health risks of artificial ...

Matthew Rhys in "The Beast in Me." (Credit: Chris Saunders/Netflix) “The Beast in Me” watches an unusual relationship unfold between recluse author Aggie Wiggs (Claire Danes) and egotistical real ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

IMAGE: For left-hander Sai Sudharsan, the decision to remove his right pad was aimed at ensuring a big front-foot stride without any protection on that leg. Photograph: BCCI/X Staying true to batters' ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...

It’s time to return to Hawkins and the Upside Down one last time. After more than three years since Season 4 came out, “Stranger Things” returns with its fifth and final season on Netflix. Season 5 ...

Critical Role‘s Campaign 4 is officially here. The fourth core chapter of the beloved TTRPG actual play series has arrived, and this time, it’s helmed by Brennan Lee Mulligan—yes, for the first time ...

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...